secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001558370-24-015441
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx secures MHRA pathway for AAV-AIPL1 approval without further studies; Q3 net loss $39.3M
--------------------------------------------------------------------------------

- AAV-AIPL1 MAA under exceptional circumstances agreed with MHRA; no further clinical studies required for UK approval.
- 11 blind children treated with AAV-AIPL1 all gained vision within 4+ weeks; FDA discussions initiated for similar US pathway.
- AAV-GAD bridging study met safety endpoint; 18-point improvement in UPDRS Part 3 'off' score (p=0.03) at Week 26.
- Three FDA Rare Pediatric Disease Designations awarded for AIPL1, BBS10, and RDH12 programs.
- Cash $122.9M + $3.3M receivables; net loss $39.3M ($0.55 per share) vs $44.3M ($0.74) YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024015441/0001558370-24-015441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024015441/mgtx-20241113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer